International Pharmaceutical Federation
Annual Report 2018

Working towards sustainable health for all
CONTENTS

A digital version of this annual report, which contains hyperlinks, can be found at http://bit.ly/FIPAr18 or can be accessed by scanning this QR code.

FOREWORD FROM THE PRESIDENT 3
SNAPSHOTS 2018 4
ABOUT FIP 8
MEMBERSHIP 10
VIGNETTES 2018 12
Focus on our profession and practice 12
Health benefits for our communities 14
Education and human resources 16
Collaborations and partnerships 18
WORLD PHARMACISTS DAY 20
78TH WORLD CONGRESS OF PHARMACY AND PHARMACEUTICAL SCIENCES 21
AWARDS 22
ELECTIONS AND COUNCIL DECISIONS 24
PUBLICATIONS 25
FIP STATESMEN ON SUSTAINABLE HEALTH FOR ALL 26
WORK IN PROGRESS 28
FINANCES 30
FOREWORD

WORKING TOWARDS SUSTAINABLE HEALTH FOR ALL

In 2018, my fellow leaders in pharmacy around the world — the FIP Council — agreed, in principle, an update to the wording of FIP’s vision, which is “a world where everyone benefits from access to safe, effective, quality and affordable medicines and pharmaceutical care.” I am proud we have defined this strategic imperative, not only because people need it — and they are the motivating reason behind all our work — but also because it requires that our profession remains viable.

It is right that FIP has taken time for intensive discussion of issues and ideas, building on our knowledge of trends. Health for all (and ensuring it continues once we reach this goal) requires us to work on sustainability, and the greatest guarantee of sustainability is policies that lay down global, regional and national regulations.

Last year, FIP contributed to policymaking, including doing some of the essential foundation work required. We have continued to lead in the area of health workforce transformation, and it was great to hear, for example, Dr Tedros Adhanom Ghebreyesus, director-general of the World Health Organization, refer ministers to our work on pharmacy workforce trends and our workforce development goals when he presented pharmacists as a solution to the global shortage of medicines and vaccines (see p5).

We have picked up pace advocating and facilitating the role of pharmacists in vaccination, and we have continued to work with the WHO’s Health Workforce Department and its Gender Equity Hub. Achieving gender equality and empowering women and girls is one of the United Nations’ 17 Sustainable Development Goals. This is an issue particularly close to my heart, and I am so pleased that, in the final month of my presidency, we were able to publish the findings of FIP’s Working Group on Women and the Responsible Use of Medicines. It is my hope that this report (see p15) will lead to an FIP statement of policy that will bring greater recognition to how pharmacists empower informal caregivers, who are mainly women. Only by working together — healthcare professionals, authorities, citizens — can we bring about a sustainable future in health.

Carmen Peña
President, International Pharmaceutical Federation
(to 6 September 2018)

It was an honour to be elected president of FIP in September 2018, and I am fortunate to be able to build on the work of immediate past president Carmen Peña. I would like to thank all those who have contributed to FIP over the past year. Our collective achievements are highlighted in the pages of this annual report. It was the groundwork of many of our members that led to some of the significant developments during the first four months of my presidency. To name but one, our federation’s presence at the Declaration on Primary Health Care at Astana, Kazakhstan, was of great value to the future of our profession.

I would also like to thank the FIP members charged with the responsibility of creating our new strategic plan in 2018 and FIP’s CEO for the current draft, which is outward facing, collaborative, enabling and assertive. I am building on all this work in order to ensure that our federation — which gathers science, practice and education under one roof — can be used with the most impact towards the goal of “health for all.”

Dominique Jordan
President, International Pharmaceutical Federation
(from 7 September 2018)
ROLE IN WOMEN’S HEALTH AMPLIFIED

Medication reviews for pregnant women in Germany, screening for breast cancer in Jordan, and supplementation programmes to prevent maternal anaemia in Tanzania are examples of how pharmacists are leading initiatives that support women presented by FIP at the 142nd session of the World Health Organization’s Executive Board, Geneva, Switzerland. FIP also brought the board’s attention to the value of pharmacists in supplying emergency contraception and promoting breastfeeding. We highlighted the importance of a global system for shortages reporting and commented on the WHO’s programme of work for 2019–23, focusing, in particular, on patient safety.

Full statements:

- Shortages of medicines and vaccines
- Women’s, children’s and adolescents’ health strategy
- WHO’s draft programme work

(on behalf of the World Health Professions Alliance)

DISTRIBUTORS ENGAGED ON MEDICINES SHORTAGES

FIP’s recommendations for mitigating medicines shortages were presented by our interim CEO and professional secretary Ema Paulino at the 7th Pharmaceutical Distribution Forum, Madrid, Spain. Among these are that each country should establish a publically accessible means of providing information on medicines shortages. Ms Paulino also drew attention to FIP’s publication “Reporting medicines shortages: Models and tactical options.”

PHARMACISTS’ VALUE IN VACCINATION RECOGNISED BY EICA

Pharmacy-based interventions to increase vaccines uptake in older people was the subject of the European Interdisciplinary Council on Ageing’s (EICA) main meeting in 2018. FIP chaired a session addressing vaccine storage and cold chain monitoring, new technologies and the role of community pharmacists around the world. “It is important to remember that many times, pharmacists are respected, well known members of the community… and often times they are the most accessible healthcare professional many people know,” said EICA president Gaetano Crepaldi.
FIP explained the vital contribution that pharmacists make to patient safety to health ministers at the Patient Safety Global Ministerial Summit in Tokyo, Japan. We drew attention to our work supporting local strategies for effective patient safety interventions and capacity building, and emphasised that patient safety is one of the most important components of healthcare delivery. The outcome of the summit, the *Tokyo Declaration on Patient Safety*, published in November, was endorsed by over 30 countries. FIP was among 10 global organisations also supporting the declaration. “This declaration will serve to facilitate patient safety as an integral document amplifying the political commitment towards the achievement of universal health coverage,” said Zuzana Kusynová, FIP policy advisor and project manager.
Advancement of the pharmaceutical workforce is a basis for enhancing patient care and health system deliverables, and requires education and training infrastructures to be in place. This was the subject of a workshop delivered by FIP at the Life Long Learning in Pharmacy conference organised by the Australian Pharmacy Council in Brisbane. It was great to see the council encouraging authors of its conference abstracts to assign FIP’s Pharmaceutical Workforce Development Goals to their submissions.

Argentinian pharmacists are taking bold steps to diversify pharmacists’ scope of practice, but are also challenged by pressures to deregulate pharmacy ownership and planned distribution. Our professional development and advocacy manager Gonçalo Sousa Pinto travelled to Buenos Aires to support our member organisation, the Argentinian Pharmaceutical Confederation (COFA), in advocating for a professional, pharmacist-led and patient-centred community pharmacy model. We shared current international trends on implementation and remuneration of professional services by community pharmacists, and, at COFA’s request, provided a paper signed by the FIP president, setting out the implications of different policies on the regulation of pharmacy ownership and distribution. COFA used this document to defend a case in the supreme court, which challenged a policy of independent pharmacist-owned pharmacies.

Governments must work more with pharmacists on providing harm reduction services and fully involve them in the development of any policies regarding medical or recreational cannabis, FIP said in a new Statement of Policy. This statement was extremely timely, given the escalating number of deaths caused by the non-medical use of opioids. Moreover, given the increasing discussions on cannabis policies around the world, the statement made clear that, where pharmacies are considered to be the best option for the supply of cannabis for recreational purposes, this approach must only be developed in consultation with pharmacists, with due regard for their ethical obligations and standing in their communities.
Building sustainable primary health care is one of four key pledges contained in the Declaration of Astana, which was endorsed by heads of state and government and ministers at a global conference in Kazakhstan. FIP was part of the global community that renewed political focus on primary health care for all at this historic meeting, where our officers explained the contributions to health pharmacists make as an integral part of a modern primary healthcare system, such as through pharmaceutical triage and pharmacy services for people with long-term conditions. The declaration, to which FIP contributed, will inform the United Nations General Assembly high-level meeting on universal health care in 2019.

FIP launched a [Workforce Development Hub](#) (WDH) to progress pharmacy workforce transformation around the world. Headed by Ian Bates, professor of pharmacy education at University College London, UK, the hub brings together experts in workforce and education to: expand the global evidence base in these areas; facilitate the needs-based, country-level implementation of FIP Education tools and the outcomes of the Global Conference on Pharmacy and Pharmaceutical Sciences Education in 2016; increase stakeholder engagement, knowledge exchange and partnership building; and monitor progress and evaluate impact and implementation. Focal areas include academic and institutional capacity, quality assurance and advanced practice and specialisation.

Plans for a new FIP forum to focus on new technologies and the place of digital technologies in pharmacy were announced by FIP president Dominique Jordan at the European Pharmacists Forum in Monaco. Mr Jordan said that new technologies will have a big impact on the daily work of community pharmacists and our profession should be leaders in adopting and adapting them. Their potential contribution to delivering sustainable health care for all should be harnessed. The forum was established in May 2019.
WHO WE ARE
The International Pharmaceutical Federation (FIP) is the global federation of national associations of pharmacists and pharmaceutical scientists, with 144 member organisations. We also have an academic institutional membership.

FIP is a non-governmental organisation that has been in official relations with the World Health Organization since 1948.

WHAT WE DO — VISION AND MISSION
FIP’s vision is a world where everyone benefits from access to safe, effective, quality and affordable medicines and pharmaceutical care.

Our mission is to improve global health by supporting the advancement of pharmaceutical practice, sciences and education. Examples of what we do and the impact of our work can be found throughout the pages of this annual report.

“A world where everyone benefits from access to safe, effective, quality and affordable medicines and pharmaceutical care.”

HOW WE WORK — STRUCTURE
FIP’s activities can be divided into three main areas — science, practice and education — although there is increasing collaboration between these areas. Work to advance the pharmaceutical sciences is primarily done through 10 special interest groups (SIGs) led by the Board of Pharmaceutical Sciences. There are SIGs for:

- **Analytical sciences and pharmaceutical quality**
- **Biotechnology**
- **Drug design and discovery**
- **Formulation design and pharmaceutical technology**
- **Natural products**
- **The new generation of pharmaceutical scientists**

- **Pharmacokinetics, pharmacodynamics and systems pharmacology**
- **Pharmacy practice research**
- **Regulatory sciences**
- **Translational research and precision medicine**

Another of our objectives is to advance pharmacy practice in all settings, and this is done through the projects and initiatives of eight pharmacy practice sections (led by the Board of Pharmaceutical Practice). There are sections for:

- **Academic pharmacy**
- **Clinical biology**
- **Community pharmacy**
- **Health and medicines information**
- **Hospital pharmacy**
- **Industrial pharmacy**
- **Military and emergency pharmacy**
- **Social and administrative pharmacy**

The reform of pharmacy and pharmaceutical sciences education in the context of pharmaceutical workforce development is a third objective, and this is the purpose of FIP Education (FiPEd), which includes academic institutional members (leaders at schools of pharmacy and pharmaceutical sciences) and a Workforce Development Hub of experts on specific education and workforce topics.

FIP directs particular effort to young pharmacists and the preparation of congresses, through its Young Pharmacists Group and Congress Programme Committee, respectively. In addition, among the boards, sections, SIGs and committees are ad hoc working and focus groups.
FIP is governed by a Council and Bureau (board). The Council is FIP’s highest administrative organ and all member organisations have voting rights (Our observer organisations participate in the Council but cannot vote.) The Council also includes representatives from the FiP sections and the Bureau. The Bureau consists of 14 elected officers (plus the FIP chief executive officer, ex officio) as follows:

**President**
Mr Dominique Jordan (Switzerland)

**Chief executive officer**
Dr Catherine Duggan (Netherlands)

**Immediate past president**
Dr Carmen Peña (Spain)

**Scientific secretary**
Prof. Giovanni Pauletti (USA)

**Professional secretary**
Ms Ema Paulino (Portugal)

**Chair of FIP Education**
Prof. William Charman (Australia)

**Chair of the Board of Pharmaceutical Sciences**
Prof. Tatsuro Irimura (Japan)

**Chair of the Board of Pharmaceutical Practice**
Mr Paul Sinclair (Australia)

FIP’s day-to-day activities are managed by an executive committee and a team of staff at our headquarters in the Netherlands, supported by an extensive global pharmacy and pharmaceutical sciences network and our partnerships. Individual annual reports of the SIGs and sections are available at [www.fip.org](http://www.fip.org).
FIP MEMBERSHIP

THROUGH OUR MEMBERSHIP, FIP HAS PRESENCE IN 153 COUNTRIES AND TERRITORIES. THIS COVERS OVER 7.4 BILLION PEOPLE.

- Member organisations: 144
- Academic institutional members: 160
- Observer organisations*: 21
- Individual members: 3,660

* A full list of FIP observer organisations can be found at: https://bit.ly/2IRuTGC
NEW MEMBER ORGANISATIONS
At its meeting in September 2018, the FIP Council admitted five new member organisations:

- Association of Community Pharmacists of Nigeria
- Cuban Society of Pharmaceutical Sciences
- Kosova Chamber of Pharmacists
- Malta Chamber of Pharmacists
- Pharmaceutical Association of Liberia

A full list of FIP member organisations can be found at https://bit.ly/3IPxK2G.

NEW ACADEMIC INSTITUTIONAL MEMBERS
FIP welcomed the following schools of pharmacy as academic institutional members in 2018:

- Ajman University (UAE)
- China Pharmaceutical University (China)
- Dongguk University (Republic of Korea)
- East Tennessee State University (USA)
- European University of Lefke (Cyprus)
- International Medical University (Malaysia)
- Kakatiya University (India)
- Keimyung University (Republic of Korea)
- Middle East University (Jordan)
- Mongolian National University of Medical Sciences (Mongolia)
- Nihon University (Japan)
- Northeastern University (USA)
- Philadelphia College of Osteopathic Medicine (USA)
- Queensland University of Technology (Australia)
- Shenandoah University (USA)
- Tianjin University (China)
- University Business Academy in Novi Sad (Serbia)
- University of Nicosia (Cyprus)
- University of North Texas System (USA)
- University of Witwatersrand (South Africa)
- Zarqa University (Jordan)

A full list of FIP academic institutional members can be found at http://bit.ly/2qaQayA.

Prof. Arianit Jakupi, president, Kosova Chamber of Pharmacists

"Being part of this large family of health professionals from around the world gives us access to the latest scientific achievements, professional expertise and mutual co-operation, thus enabling continuous development of the pharmacy profession that will follow and harmonise with that of more developed countries. This — for Kosovo as a new country — is very significant at this stage of health sector reform."

Dr Mohd Zulkefeli Bin Mat Jusoh, dean, International Medical University, Malaysia

"International Medical University (IMU) in collaboration with FIP, aspires to nurture the pharmacy profession to address the needs of health care in digital dominance. Through this institutional membership, IMU becomes interconnected with other academic institutions to work on advancing the growth and development of pharmacy education on a global platform."
DRAFTING NEW PHARMACY LAWS

FIP contributed to the drafting of new legislation to regulate community pharmacies in Montenegro in May. Policy options, international models and key principles to be considered when drafting the new law were presented by Gonçalo Sousa Pinto, FIP's professional development and advocacy manager, at a consultation hosted by the World Health Organization country office and the WHO Regional Office for Europe in Podgorica. Also present at the meeting was the Pharmaceutical Chamber of Montenegro — a FIP member organisation. Case studies from Malta and Slovenia were presented by the respective ministries of health.

Mrs Milanka Zugic, president, Pharmaceutical Chamber of Montenegro

“This new legislation represents the first, significant step towards law-based regulation of the pharmaceutical profession and establishes pharmaceutical care as an integral part of the profession. The evident agreement of FIP with the points regarding the new law made by the chamber at the consultation was highly valuable.”

PROVIDING A PLATFORM FOR YOUNG PHARMACEUTICAL SCIENTISTS

October saw the launch of a new FIP special interest group: the New Generation of Pharmaceutical Scientists. The goal of this group is to enable young scientists to influence the future of the global pharmaceutical sciences community. It will strive to connect young scientists in academia, industry, and government and offer an opportunity for global networking. Another goal is to serve as a platform for mentorship of future leaders in pharmaceutical sciences with a global vision.

INSPIRING PROFESSIONALISM

It was a pleasure to support the Algerian Pharmacy Federation (FAP) at its third annual congress, held in Algiers in November. Founded in 2016, FAP is a young association that works to promote the added value of pharmacists in its country. Making his inaugural appearance at the congress, FIP president Dominique Jordan said that the challenges for pharmacy are many, but the opportunities great. Mr Jordan spoke of a “new tsunami” hitting pharmacy — liberalisation, technology and artificial intelligence — and urged participants to quickly consolidate their role as a medical profession, service providers and gateway to the healthcare system, taking ownership of new trends, technologies and logistic models. He urged Algerian pharmacists to become “pioneers of the evolution of the profession”, adding that their example would be followed by neighbouring countries.

Dr Redouane Soualmi, general secretary, FAP

“The presence of FIP president Dominique Jordan and FIP Education manager Nilhan Uzman was a great opportunity for Algerian pharmacists and especially young pharmacists to get to know about FIP’s global vision and get inspired to be more involved and committed to make changes in pharmacy.”

FOCUS ON OUR PROFESSION AND PRACTICE

FOCUS ON OUR PROFESSION AND PRACTICE

FIP continued to advocate for the role of pharmacists in supporting self care in 2018. “Pharmacists, now more than ever, are empowering patients to take better care of themselves. [They] need to be fully incorporated into health systems and to be properly remunerated for delivery of their self-care services,” Ema Paulino, FIP’s professional secretary, told delegates at the Sanofi Retail Conference in London, UK, in June. Ms Paulino shared data on medicines dispensing regulation and accessibility to pharmacies, highlighted the increasing types of pharmacy services being implemented and remunerated, and explained how these fit into health system strategies giving more prominence to primary and community care.
SHARING EXCELLENCE IN PHARMACY PRACTICE

Excellence in pharmacy practice was brought to the attention of Oman’s Ministry of Health Directorate General of Medical Supplies by FIP vice president Eeva Teräsalmi in February. Speaking at the sultanate’s 8th Pharmaceutical Care Conference, in Muscat, she gave insights into how community pharmacies are managing non-communicable diseases. An international overview of how pharmacy services contribute to the efficiency of healthcare systems was presented to the leadership of Spanish pharmacy organisations, in Santiago de Compostela, Spain, in July. “It is important to align pharmacy services with public policies and to develop remuneration mechanisms to render pharmacy services sustainable,” Gonçalo Sousa Pinto, FIP’s professional development and advocacy manager, said in the keynote address.

WORKING ON “HIGHEST LEVEL” HOSPITAL PRACTICE

Implementing sustainable improved pharmacy services in hospitals in developing countries was on our Hospital Pharmacy Section’s 2018 agenda. Continuing to embed the Basel Statements around the world, the section embarked on a project named the “Bold Audacious Goal”, which led to collaborative research being conducted in Namibia to assess hospital base-line compliance with the statements. This is the beginning of a long-term goal to implement the Basel Statements in Namibia, Pakistan and other developing countries collaborating with other projects and organisations such as Pharmabridge and the William Davidson Institute, Michigan, USA.

COLLABORATING ON PHARMACY REGULATION

Professional organisations with regulatory functions play a decisive role in overseeing the profession and setting standards of practice, ethical conduct and public protection. They do this to ensure patient safety and optimal health outcomes. Recognising the need for international collaboration and coordination in this area, in September, FIP established a permanent forum for pharmacy professional regulators, currently chaired by Cdr Sylvain Grenier of the Canadian Armed Forces.

SUPPORTING USE OF INTERNATIONAL NONPROPRIETARY NAMES

FIP contributed to the development of International Nonproprietary Names (INN) for medicines at the 10th meeting of the World Health Organization School of INN in Madrid, Spain, in November. The objective of the meeting was to finalise three INN teaching modules: teaching pharmacology with INN and their stem; teaching for biological medicines; and teaching the INN system. FIP will be reviewing the modules and providing advice from the pharmacists’ perspective. Representing FIP was Marta Hernandez, associate professor, Ramon Llull University, Spain, an academic institutional member of FIP. Earlier in the year, we were at the WHO’s 66th Consultation on INNs for Pharmaceutical Substances in Geneva, Switzerland, telling other experts how generic medicines use is boosted by pharmacists, with economic savings for payers, while ensuring quality and safety of medicines.

Dr Raffaella Balocco, group lead of the World Health Organization INN Programme

“The use of INNs strengthens the role of the pharmacist, empowers the patients and facilitates access to safe, effective and quality medicines. FIP support in INN prescribing (also known as generic prescribing) is an appreciated contribution to global public health.”

Eeva Teräsalmi: Excellence in pharmacy practice

Ms Kefe Odukuye, hospital pharmacist, Nigeria, and participant in the Hospital Pharmacy Section/Pharmabridge Basel Statement Site Project

“I wish to express my sincere appreciation to [FIP] for making it possible for me to have this life-changing learning experience at UNC Medical Center/Eshelman School of Pharmacy [North Carolina, USA]. I will do all within my capacity to put all I have learnt to good use and will work at achieving all my action plans.”

Vignettes 2018
HEALTH BENEFITS FOR OUR COMMUNITIES

FACILITATING IMMUNISATION RIGHTS

Disease prevention is key to sustainable health for all, and ensuring vaccine coverage is an essential component. In 2018, we made huge steps in supporting colleagues around the world in expanding their role in immunisation. In January, for example, we held a special event (#FIP4Vaccination) in Amsterdam, Netherlands, providing the tools for pharmacy leaders from almost 30 countries to learn how to advocate for and implement pharmacy vaccination services successfully.

We also ensured our presence at global events where vaccination and related innovation, regulation and policies were discussed, such as at the World Health Organization Winter Meeting in Utrecht, Netherlands (January), organised by the WHO Collaborating Centre for Pharmaceutical Policy and Regulation, and at the Gerontological Society of America’s Scientific Meeting in Boston (November), organised by the International Longevity Centre.

Ms Scarlett Pong, president, Pharmaceutical Society of Hong Kong SAR, China.

“[The FIP event in Amsterdam] was an exceptional and practical seminar on vaccination advocacy, which was very stimulating. We are planning to do it in Hong Kong after all your motivation! Special thanks to FIP for a wonderful, well-organised seminar.”

COMBATING SUBSTANDARD AND FALSIFIED MEDICINES

A new project to raise awareness of substandard and falsified medicines among pharmacists in Sub Saharan Africa was on FIP’s agenda in May. The World Health Organization invited FIP to collaborate on a new project to increase pharmacists’ awareness of substandard and fake medicines. According to the WHO Global Surveillance and Monitoring System for substandard and falsified medical products, over 1,600 substandard or falsified medical products had been reported from 100 countries in a period of four years, with almost 50% of reports coming from the African region. The vital role that pharmacists play in assuring people’s safety, actively participating in the fight against fake medicines, was conveyed to the Council of Europe later in the year when Ema Paulino, FIP’s professional secretary, spoke at a meeting of the Committee of Experts on Minimising Public Health Risks Posed by Falsification of Medical Products and Similar Crimes in Strasbourg, France, in November.

Mr Michael Deats, acting coordinator, safety and vigilance, World Health Organization.

“The WHO is pleased to be working with FIP and other partners on the issue of substandard and falsified medical products. Education and awareness are key components in addressing the issue. Pharmacists are one of the most important groups in the identification and reporting of suspected substandard and falsified medical products. Together with FIP, we wish to build a compulsory component in the pharmacy curriculum, specifically focused on substandard and falsified medical products, for piloting in a group of African universities. The WHO is looking forward to working together on this initiative to better protect patients and consumers and safeguard public health.”

COMBATING ANTIMICROBIAL RESISTANCE

FIP contributed to the education of health professionals in the fight against antimicrobial resistance (AMR) in 2018. A competency framework for health workers’ education and training on antimicrobial resistance was published by the World Health Organization in June and is a direct outcome of our work with the WHO on AMR. The framework identifies a range of competencies needed to combat the spread of AMR, and recognises the important role of pharmacists in this effort.
PREVENTING DENGUE DEATHS

Cases of dengue are on the increase, and are no longer confined to the tropics. “Explosive outbreaks” have been occurring, according to the World Health Organization. Severe dengue has caused serious illness and death in children. Dengue vaccines represent a major advance in the control of this mosquito-borne disease, with the first becoming available in 2015. FIP, working with the Pharmaceutical Forum of the Americas, provided pharmacists around the world with a webinar, in March, enabling them to apply technical and scientific criteria in the provision of services for the detection, treatment and prevention of dengue. Pharmacists’ involvement in vector control strategies was revisited in June when we provided the platform for another forum webinar on the pharmacist’s role in the control of arboviruses. In 2018, FIP provided over 30 webinars, with topics including pain management (from FIP’s Community Pharmacy Section) and strengthening supply chains (from FIP’s Military and Emergency Pharmacy Section).

IMPROVING MEDICATION SAFETY

FIP contributed to the revision of the World Health Organization’s “Improving medication safety” document, in March. This document targets all healthcare professionals and will facilitate the development of a comprehensive interprofessional edition of the medication safety curriculum. In November, FIP’s CEO Catherine Duggan gave a global view of medication safety work by pharmacists and chaired the 8th Royal Pharmaceutical Society Medicines Safety Conference, in Cardiff, UK, where speakers included the Welsh Cabinet Secretary for Health and Social Services as well as Wales’s chief pharmaceutical officer. Dr Duggan continued work in this area during a visit to Dublin, Ireland, in the same month, at a medication safety event organised by Trinity College School of Pharmacy and Pharmaceutical Sciences exploring how the country’s pharmacists can lead and respond to the WHO 3rd Global Patient Safety Challenge.

ENCOURAGING RESPONSIBLE USE OF MEDICINES

Pharmacists and their organisations were encouraged to look into possibilities for championing women and the responsible use of medicines, following the publication of our report "Pharmacists supporting women and responsible use of medicines: Empowering informal caregivers", in September. Women are often the ones who assume the health responsibilities for their households and families and who visit pharmacies. The research by FIP’s Working Group on Women and the Responsible Use of Medicines found that health systems rely heavily on unpaid and informal work that disproportionately falls to women, and because of the multifaceted role that these informal caregivers play, they need a range of support services to improve their caregiving skills. As the most accessible healthcare professionals, pharmacists are in an ideal position to empower women in these roles.

INCREASING QUALITY OF LIFE THROUGH SCIENCE

Leading scientists from all over the world shared up-to-date information on oral drug absorption, the strategy for oral drug development and the regulation of oral drug products at the third international symposium on Bioavailability/Bioequivalence of Oral Drug Products organised by the Bioavailability/Bioequivalence Focus Group (part of FIP’s Special Interest Group on Regulatory Science) in October. Held in Lisbon, Portugal, the symposium emphasised the importance of integrating biopharmaceutical science into the development of oral drug formulations. With the right science in biopharmaceutics and advanced technologies for oral drug formulation, it is possible to maximise therapeutic effects and minimise patient inconveniences to increase quality of life.

Dr Joseph Kathare, MTM pharmacist, Kiambu County, Kenya

*Being a provider of medication therapy management (MTM) services in Kenya, the webinar on pain management empowered me with more skills and knowledge on how to conduct comprehensive medication reviews with patients who are on chronic medications for pain management such morphine, pethidine and dihydrocodeine.*
EDUCATION AND HUMAN RESOURCES

REINVIGORATING PHARMACY EDUCATION IN AFRICA

In October, FIP contributed to the Strategic Partnership for Higher Education Innovation and Reform (SPHEIR) Portfolio Workshop in Nairobi, Kenya, where discussions were held on methodologies and plans for pedagogical capacity building, curriculum design, policy engagement and influence, and access and equity in higher education. The SPHEIR is supported by the UK Department of International Development and FIP is an official partner of the Nottingham-Kenya Partnership SPHEIR project, funded by UKAid, which aims to reinvigorate the pharmacy and chemistry curriculum in Kenyan higher education courses and help to address skills shortages in the workforce. Catalysing collaborations for education is a key component of the work of FIP Education, which also brings its network and extensive expertise in education and workforce development to SPHEIR, through the FIP-UNESCO UNITWIN Centre for Excellence in Africa (CfEA). In June, in collaboration with the University of Benin, FIP organised a centre for excellence meeting in Lagos, Nigeria, to identify current gaps in pharmacy education in UNITWIN partner countries, using FIP tools such as the Pharmaceutical Workforce Development Goals. Representatives of schools of pharmacy from Ghana, Kenya, Malawi, Namibia, Nigeria and Zambia were present and action plans to close identified gaps were developed.

Dr Kennedy O. Abuga, member of the FIP UNESCO-UNITWIN Centre for Excellence in Africa and senior lecturer, University of Nairobi, Kenya

"Both FIP-UNESCO UNITWIN and SPHEIR-Kenya-Nottingham Partnership Project lay emphasis on needs-based education thus functioning synergistically and resonantly with Kenya’s pharmacy curriculum development objectives. During the upcoming curriculum revision, we will deliberately utilise FIP’s tools, resources and global network in an integrated and coordinated manner geared towards producing practice-ready graduates with the pragmatism required to cope with healthcare needs of the population and market dynamics."

ADVOCATING FOR GENDER EQUITY

Resilient health systems and universal health coverage cannot be progressed without consideration of the gender aspects of the health workforce. FIP is a proud member of the the World Health Organization’s Gender Equity Hub, which is part of the Global Health Workforce Network. We represented the hub at the Health Policy and Systems Research Agenda on Gender and Intersectionality meeting in Dubai, UAE, in April, where stakeholders gathered to address gender gaps in health systems. We also led the preparation and running of a webinar organised by the World Health Organization and Women in Global Health, in August, on “Gender transformative policies and workforce”.
**PROVIDING STRATEGIC ADVICE**

May saw the first meeting of the Global Health Workforce Network’s Strategic Advisory Committee in Geneva, Switzerland. Our FIP Education development team director Ian Bates was one of a handful of experts invited to be part of the committee, advising the World Health Organization on accelerating progress towards universal health coverage and the UN Sustainable Development Goals by ensuring equitable access to health workers within strengthened health systems through inter-sectoral engagement. Our commitment to sharing our workforce development tools, including the [Pharmaceutical Workforce Development Goals](#), continues.

Dr Jim Campbell, director, Health Workforce Department, World Health Organization

“I applaud FIP for its efforts in developing these [Pharmaceutical Workforce Development Goals](#). The clear alignment with the World Health Organization’s human resource for health policies is welcome and demonstrates strong leadership for this critical health workforce.”

**DEVELOPING PHARMACEUTICAL SCIENTISTS**

“The engagement plan for innovative pharmaceutical sciences training pathways calls upon academia, industry, regulators, patient advocacy groups, and health organisations to synergistically enhance knowledge, of future contributors to drug development,” Giovanni Pauletti, FIP’s scientific secretary (pictured), told delegates at the 8th All-Russian Scientific Conference of Students and Graduate Students in St. Petersburg, Russian Federation, in April. Prof. Pauletti’s talk focused on encouraging interdisciplinary training of the future pharmaceutical sciences workforce. “It is imperative to continue advocating support of pharmaceutical science within pharmacy… The interconnected pharmaceutical development world recognises workforce diversity as a major strength,” Dr Pauletti said. FIP was also represented by Academic Pharmacy Section president John Pieper.

**SPREADING FIP’S VISION FOR EDUCATION**

Workforce was among topics raised by FIP CEO Catherine Duggan at the Ministry of Welfare in Reykjavik, Iceland, in October, where she met with the country’s director of pharmaceutical affairs Einar Magnusson. Our CEO was visiting Iceland on occasion of the implementation of a new degree in clinical pharmacy. At a ceremony held by the Pharmaceutical Society of Iceland, the National University Hospital of Iceland, and the University of Iceland, Dr Duggan gave a presentation on workforce transformation, as well as raising issues around medicines supplies and shortages. We continue to engage with pharmacy educators around the world. In February, our vice president Jacqueline Surugue was present at a debate held by the French Pharmacy Academy on whether the training of pharmacy students is robust enough for them to face future challenges, and, in October, Patricia Acuña, a member of FIP’s Academic Pharmacy Section, presented FIP Education resources at the XI Pan American Pharmaceutical Education Conference in Quito, Ecuador.

**MAPPING FUTURE WORKFORCE NEEDS IN THE MIDDLE EAST**

Opportunities lie ahead that open the path for workforce transformation and for Jordan to lead by example in instilling change in the Middle East. A mapping exercise to identify primary workforce development needs within the Royal Medical Services in Jordan were among activities undertaken by FIP Education in October. The exercise was led by FIP Education project coordinator and researcher Lina Bader during the 9th International Conference of the Royal Medical Services in Amman, attended by physicians, nurses, dentists and allied health professionals as well as pharmacists. The exercise identified a need to set a visionary workforce development strategy, which includes focus on further developing advanced and specialist practice systems for military pharmacists and the wider national workforce.

Dr Zeid Kilani, president, Jordanian Pharmacists Association

“It’s becoming increasingly apparent that Jordan needs to rethink its national workforce development strategies, aligning with FIP and WHO’s global strategies.”
COLLABORATIONS AND PARTNERSHIPS

70 YEARS OF COLLABORATION ON GLOBAL HEALTH

In 2018, FIP celebrated 70 years of official relations with the World Health Organization. The topics of collaboration have expanded over time and cover many areas that are of major public health importance globally, such as quality of medicines, availability and responsible use of medicines, pharmaceutical workforce and pharmacy education, the fight against substandard and falsified medical products, patient-specific preparations for children, antimicrobial resistance, medicine shortages and interchangeability of generic medicines.

Dr Sabine Kopp, group lead, medicines quality assurance, essential medicines and health products, World Health Organization

“FIP has contributed to WHO and its member states through technical expertise, advocacy and joint projects. FIP’s role in the international health arena and among policymakers is visible. At least half of the world’s population still do not have full coverage of essential health services. Speaking as a pharmacist, FIP’s contribution to the global health agenda and to improving health service coverage has been and will also be in the future key, since health outcomes depend on the availability, accessibility and capacity of health workers to deliver quality people-centred integrated care.”

SETTING THE RIGHT PROFESSIONAL STANDARDS

Public scrutiny of professional work is higher than ever. The design, implementation and execution of competence assessment are essential. “Better regulation for better health” was the theme of the 2018 World Health Professions Regulation Conference, held in Geneva, Switzerland, in May. FIP jointly organised this conference with the International Council of Nurses, the World Confederation for Physical Therapy, the World Dental Federation and the World Medical Association, under the umbrella of the World Health Professions Alliance. The conference was attended by health professionals from 36 countries.

Mr Enzo Bondioni, executive director, World Dental Federation (FDI)

“Health professional regulation remains a challenge around the globe. In the dental profession, for example, we have the case of mercury: policies have been developed to phase-down the use of dental amalgam. However, these policies have been difficult to implement and regulate in certain contexts, due to lack of resources, lack of enforcement, or limited public health awareness. In the face of these obstacles, it is more important than ever to adopt a unified approach across the health professions to ensure better health outcomes worldwide.”
DELIVERING A SUSTAINABLE WORKFORCE

FIP signed a memorandum of understanding with the Commonwealth Pharmacists Association (CPA) in June, defining how the two organisations will work synergistically to advance health for the public benefit by developing the pharmacy profession. This formal commitment followed significant joint work to push forward the pharmaceutical workforce agenda.

Ms Victoria Rutter, executive director, Commonwealth Pharmacists Association

“2018 provided important opportunities for the CPA’s advocacy efforts for the profession around both the Commonwealth Heads of Government Meeting and Commonwealth Health Ministers Meeting. Our voice was significantly louder due to the support in these efforts offered by FIP. The impact we have made together is significant and resulted in a recommendation from civil society to invest in the pharmacy workforce being presented to the Commonwealth health ministers.”

PARTNERING FOR PATIENT SAFETY

Pharmacists play a key role in patient safety. July saw FIP and the Patient Safety Movement Foundation (PSMF) become partners. This alliance is in line with our goal to help implement the World Health Organization Global Patient Safety Challenge. We support the foundation’s mission to eliminate preventable deaths by 2020 and its vision “0X2020”, and this partnership allows us to build on existing work and leverage common technical expertise, as well as disseminate useful tools to a wide network of pharmacists, other healthcare professionals and patients around the world. With the common aim of achieving a culture of safety, we can encourage sharing of successful processes to eliminate preventable deaths.” FIP is represented at the PSMF’s working groups by Ramesh Walpola, a member of our Working Group on Patient Safety.

Dr David B. Mayer, CEO, Patient Safety Movement Foundation

“We value our partnership with International Pharmaceutical Federation and look forward to working closely with them in the years to come to help eliminate preventable harm and death in hospitals worldwide.”

SUPPORTING COLLEAGUES OF THE FUTURE

We are pleased to support the International Pharmaceutical Students’ Federation (IPSF) wherever we can, including at their annual conferences. In 2018, Lars-Åke Söderlund, president of FIP’s Community Pharmacy Section, and FIP’s professional development and advocacy manager Gonçalo Sousa Pinto travelled to Mendoza, Argentina, to speak at the IPSF’s 64th world congress. Dr Söderlund spoke of the value of communication during interviews with patients, improving adherence among elderly patients and the role of pharmacists in self-care, and Mr Sousa Pinto shared FIP’s messages on the greater value to public health that pharmacists who can administer vaccinations can bring.

Ms Petra Orlic, president, International Pharmaceutical Students’ Federation

“In the educational part of the [IPSF] congress, of great importance was the contribution of international speakers from FIP. They brought to IPSF members, students and recent graduates valuable information about pharmaceutical science, practice and education, their future and innovations.”

IMPROVING CARE FOR SENIORS

In November, we collaborated with the International Federation on Ageing to organise a webinar focusing on the use of medicines by seniors and the role of pharmacists in promoting adherence. The webinar highlighted international best practices around improving adherence and providing care to older adults. The webinar was attended by 291 participants.

Dr Josep Romagosa, public health officer, Health Resources and Medicines Department, Ministry of Health, Government of the Principality of Andorra

“This webinar was very interesting, as we have had several issues related to medicines use in elderly patients. After the webinar we started thinking of ways we could share the presentation with health professionals [in Andorra] to highlight these practices.”
World Pharmacists Day, which falls on 25 September, is marked by colleagues around the globe, highlighting the impact and added value of the pharmacy profession and its role in improving health to authorities, other professions, the media and the general public. Its purpose is to encourage promotion and advocacy for the role of the pharmacist in improving health in every part of the world.

“Pharmacists are your medicines experts” was the core message of World Pharmacists Day 2018, designated by the FIP Bureau. The theme emphasised that pharmacists are a trusted source of knowledge and advice, not only for patients but also for other healthcare professionals.

FIP offered free campaign materials in the six official United Nations languages, including a set of four animations outlining the value that pharmacists represent. In its eighth year in 2018, it was marked with numerous activities, including appearances on radio shows in Ghana and diabetes and blood pressure testing in a shopping centre in Mauritius.

1. Pharmacists in Bosnia and Herzegovina raised awareness of the important role of pharmacists as healthcare providers, highlighting their knowledge and expertise in medicines and round-the-clock availability.

2. Ecuador’s Health Minister joined the World Pharmacists Day celebrations.

3. The Pharmaceutical Association of Mauritius organised a “health day” with a stand for members of the public to visit for a health check-up. Over 200 people were counselled, and 35 were screened for breast cancer.
“Transforming outcomes” was the theme of FIP’s 78th World Congress of Pharmacy and Pharmaceutical Sciences, which was held in Glasgow, United Kingdom, from 2 to 6 September, and co-hosted by the Royal Pharmaceutical Society.

The congress programme included sessions on new pharmacy services, technological advances, patient safety, gene therapy, medical use of cannabis, and gender equity. It also included a Global Deans Forum and a Pharmacy Technicians Symposium.

There were 2,793 participants, including 204 speakers, from 108 countries. A record number of abstracts (713) was presented and 12 countries accredited sessions for continuing professional development/education.

Ms Halimah Isbag, Student, University of Birmingham, UK
“Attending the conference made me realise just how many career routes are available with an MPharm degree. I met pharmacists involved in technology, economics, law and journalism. It really inspired me.”

Professor Ash Soni, president, Royal Pharmaceutical Society, UK
“FIP Glasgow was an incredible experience. It was a privilege to co-host this prestigious congress and to be part of the success of collaboration between FIP and the RPS.”

The Scottish Government’s Cabinet Secretary for Health and Sport Jeane Freeman said that pharmacists’ professional commitment and clinical leadership will improve health inequalities.

19 future leaders benefited from the Young Pharmacists Group inaugural leadership workshop, organised with support from the Academic Pharmacy Section.

Delegates were able to share their professional and personal views about pharmacy at the Speaker’s Corner, organised by the Community Pharmacy Section.

The Women in Pharmacy Forum was the start of a conversation designed to progress FIP’s Pharmaceutical Workforce Development Goal 10: gender and diversity balances.

Dr Catherine Kuecker, second year ambulatory care pharmacy resident in Madison, Wisconsin, USA, and APhA Foundation 2018 Ton Hoek Scholar
“Attending the 2018 Glasgow world congress enabled me to begin my professional pharmacy involvement on a global scale and demonstrated a network to share and learn from colleagues. Congress provides a unique and invaluable experience for the globally minded!”

Mr Raj Vaidya, community pharmacist, Goa, India
“I had a fabulous time at the FIP [congress in] Glasgow. There was so much knowledge and so many ideas that I could pick up to adapt and implement in my place of practice. It was exciting to see the ‘stars’ of the pharmacy profession moving around you, and to catch up with fellow pharmacist friends from my country and around the world, meet many new ones and exchange professional views.”
RECOGNISING INNOVATION AND BEST PRACTICES

FIP grants two awards each year to its member organisations for the best pharmacy improvement and the best health promotion work.

The 2018 Best Pharmacy Practice Improvement Programme Award was shared by the Pharmaceutical Society of Singapore for an initiative that led to 80% of nursing homes in Singapore choosing to benefit from pharmaceutical care and the American Pharmacists Association (APhA) Foundation for a model of care that maximises the opportunity for pharmacists to contribute to vaccine coverage (Project IMPACT). FIP’s Health Promotion Campaign Award went to the Association of Pharmacists of Belgium for a campaign entitled “My pharmacist knows me, I sign up”, which introduced the idea of the “family pharmacist” to the Belgian population, leading members of the public to cement this special relationship with their chosen pharmacist through the signing of a contract.

Mr Benjamin Blumli, senior vice president, Research and Innovation, APhA Foundation

“This award is a huge recognition of the hard work of all Belgian community pharmacists and a crucial step towards implementing advanced pharmaceutical care in Belgium.”

Mr Frank Crasson, marketing and communication director, Association of Pharmacists of Belgium

“The results of Project IMPACT Immunizations validate that pharmacists can help identify and resolve unmet vaccination needs by recommending appropriate vaccines based on a person’s individual needs, particularly when equipped with innovative point-of-care technologies that support a streamlined process of care. We are encouraged by the outcomes of the pilot and look forward to scaling this model in more community pharmacy practice settings.”

Ms Grace Lee (pictured right), chair, Intermediate Long-term Care Pharmacist Workgroup, Pharmaceutical Society of Singapore

“This international award is a milestone achievement for the Pharmaceutical Society of Singapore Intermediate Long Term Care Pharmacists Workgroup. It is a great encouragement to us as advocates to continue to collaborate with various stakeholders to improve pharmaceutical care for the benefit of the public.”
TOWARDS SUSTAINABLE HEALTH FOR ALL

OTHER AWARDS
FIP also made the following awards in 2018:

- **André Bédat award**
  Prof. Lloyd Sansom (Australia)

- **Distinguished Science Award**
  Prof. Bert Leufkens (Netherlands)

13 FELLOWSHIPS (pictured below, left to right)
- Mr John Bell (Australia)
- Prof. Tina Brock (Australia/USA)
- Prof. Oliver Bugnon (Switzerland)
- Mr Ulf Janzon (Sweden)
- Dr Peter Kielgast (Denmark) [received by Bente Frøkjær]
- Dr Joseph A. Oddis (USA) [received by Paul Abramowitz]
- Mr Jean Parrot (France) [received by Michel Buchmann]
- Prof. Marion Schaefer (Germany)
- Mr Abdul Latif Sheikh (Pakistan)
- Dr Dieter Steinbach (Germany)
- Dr James Stevenson (USA)
- Dr Boyan Todorov (Bulgaria/Netherlands)
- Prof. Toyin Tofade (USA)
The FIP Council adopted the following policy statements:

- "The role of pharmacists in reducing harm associated with drugs of abuse", which calls on governments to work more with pharmacists on providing harm reduction services and fully involve them in the development of any policies regarding medical or recreational cannabis.
- "Pharmacists’ authority in pharmaceutical product selection: therapeutic interchange and substitution", which makes clear that this authority should also apply to biological medicines. The use of generic names is still encouraged, but the revised statement gives focus to the use of international non-proprietary names in particular.

ELECTIONS AND COUNCIL DECISIONS

The FIP Council, through which all member organisations have voting rights, meets once a year. At the Council meeting, held in Glasgow, UK, in September 2018, elections were held and a number of decisions were made.

Elections
Mr Dominique Jordan was elected FIP president. Mr Carlos Lacava (Uruguay), Ms Samira Shammas (Jordan) and Prof. Ashok Soni (UK) were elected as vice presidents on the FIP Bureau (board).

Decisions
The FIP Council ratified Mr Paul Sinclair as chairman of the Board of Pharmaceutical Practice.
The Board of Pharmaceutical Sciences Strategic Plan sets out the BPS’s vision to be the global focal point for the promotion of pharmaceutical sciences and contribute to the promotion of world health. It outlines strategic objectives and specific activities.

FIP guidelines for dissolution testing of solid oral products (by FIP’s Focus Group on Dissolution/In Vitro Drug Release), summarise the considerations for development and validation of a suitable dissolution method and how to obtain a biowaiver.

International Pharmacy Journal (two issues: “Healthy ageing”, June, and “Transforming outcomes”, November)

“Pharmacist’s authority in pharmaceutical product selection: therapeutic interchange and substitution” (FIP Statement of Policy)

“Pharmacists in the supply chain: The role of the medicines expert in ensuring quality and availability” gives a global overview of the roles of pharmacists in supply chains in low-, middle- and high-income countries. It points out that investment in training and education are needed to strengthen these roles, and details the competencies required.

“Pharmacists supporting women and responsible use of medicines” focuses on the potential for pharmacists to support women in their often overlooked role as informal caregivers, with examples from different countries.

Pharmacy Education Journal (44 papers)

“Pharmacy Workforce Intelligence: Global Trends Report 2018” presents the findings from the largest retrospective study of pharmacy workforce capacity conducted by any organisation to date.

“The role of pharmacists in reducing harm associated with drugs of abuse” (FIP Statement of Policy)

Translations of “Transforming pharmacy and pharmaceutical sciences education in the context of workforce development”, the report of FIP’s Global Conference on Pharmacy and Pharmaceutical Sciences Education in Nanjing, China, 2016, were made available in Portuguese, Chinese and Spanish.

“Use of medicines by the elderly: The role of pharmacy in promoting adherence” reviews pharmacy programmes and services to improve adherence in this growing patient population. The report, also available in Spanish, is intended as a tool to promote pharmacists’ roles in tackling adherence issues to authorities.

World Congress of Pharmacy and Pharmaceutical Sciences video series (nine interviews) and over 700 abstracts

Sabrina Arena, of the Institute for Cancer Research and Treatment in Turin, Italy, explained cancer cell resistance.
In 2018, five FIP Bureau members ended their terms of service. We acknowledge their work and dedication to our federation, and asked them for their views on the profession delivering sustainable health care for all.

**Dr Michel Buchmann** (Switzerland), immediate past president 2014–18

“

The future professional revolution for pharmacists will depend on their integration into primary care. Pharmacists cannot replace doctors, but they can be integrated into primary care by organising the best pharmaceutical triage possible with a dual purpose: referring patients who require medical care to doctors, and taking care of people who can benefit from pharmaceutical care. Pharmacists’ traditional mission will always be to guarantee the population’s access to quality medicines accompanied by the necessary advice, but with a close collaboration with other health professions they could develop new activities. FIP plays a fundamental role in opening and coordinating these new areas of work to deliver health for all.

**Mr Andrew L. Gray** (South Africa), vice president 2014–18

“A challenge for every health system at this time is the attainment of universal health coverage. Integral to that effort is the ability to provide access to affordable, quality essential medicines and to ensure their responsible use. That places pharmacists, pharmaceutical scientists, their professional associations and FIP at the very centre of global policy. FIP not only needs to ensure that it is ‘at the table’, but that is has developed and can articulate for cogent policy positions on such challenging issues as medicine pricing, systems of innovation and reward, antimicrobial stewardship, and medication safety.”
In Uruguay, we know that the different levels of the healthcare system are not well connected. Each community has different needs. I live in a region where patient data are not fully available or not being shared for all health professionals. The role and the development of health services at primary level is still a big challenge. In FIP, we share common values. FIP is a global organisation, where you can find colleagues with the motivation, the competencies and the commitment to build a better future.

As the most accessible healthcare professionals, pharmacists have a logical and obvious role in delivering sustainable healthcare for all. They can contribute through wellness and health risk management and improving the effectiveness of medicines. There is a gap between the potential effectiveness of medicines and their actual effectiveness; pharmacists can close this gap by resolving medicine-related problems. They can also improve the safe use of medicines.

Japan has had a national health insurance system for 60 years, providing health coverage for its citizens. But our country is fast becoming a super-aged society and our pharmacists must prepare for this. Medical health expenditure will increase every year, presenting a big problem for national budget and continued good organization of the social security system. We need to ensure easy access to medicines at an appropriate price, anytime, anywhere, and by anybody. Sustainable health for all will also involve preventing polypharmacy and antimicrobial resistance as well as effective use of over-the-counter medicines in the community. FIP has been working on all these measures. FIP strongly contributes to making joint statements with organisations such as the World Health Organization and the World Medical Association, which have been particularly valuable for engaging many countries.
WORK IN PROGRESS

DURING 2018, FIP ALSO WORKED ON THE FOLLOWING AREAS:

GENDER EQUITY AND DIVERSITY

We continued to work with the WHO Gender Equity Hub to address gender inequities and biases in the pharmacy and pharmaceutical sciences workforce. We contributed to a *Lancet* paper on gender transformative change in the healthcare workforce (published in February 2019) and provided pharmacy information to the hub’s first report (published in March 2019), which contains case studies, programmes, policies and strategies on workforce gender equity.

FIP STRATEGIC PLAN

During 2018, the work to develop, agree and implement FIP’s strategic imperatives progressed. A version of FIP’s strategic plan was discussed and agreed in principle by the FIP Council in Glasgow 2018. Following the Council meeting in Glasgow, the FIP Bureau agreed that there would be a further chance to comment and feed in ideas around the strategy imperatives and actions by the end of 2018, to be discussed and agreed by Bureau in March 2019, ready for approval at the 2019 Council meeting. In the meantime, the strategy has been operationalised through our 2019 business plan with 10 cross-FIP programmes of work to align our activities with our new vision and mission.

FUTURE CONGRESSES

Work is under way for our 79th annual congress, which will be held in Abu Dhabi, UAE (22–26 September 2019; “New horizons for pharmacy: Navigating winds of change”) and the Pharmaceutical Sciences World Congress in Montreal, Canada (22–27 May 2020; “Smart therapeutics for a complex world”), as well as for our 80th annual congress, which will be held in Seville, Spain, in 2020.

GLOBAL PHARMACY OBSERVATORY AND FIP ATLAS

The Global Pharmacy Observatory (GPO) will be FIP’s repository of data and source of intelligence, which we will seek to improve through appropriate technology, add to, refine and grow through partnerships. The FIP Atlas will be a platform for showcasing our members’ needs and priorities (supported by the data from the GPO), allowing FIP to identify opportunities for developing pharmacy with, for and through our member organisations.
WORKFORCE TRANSFORMATION AND DEVELOPMENT

FIP’s Workforce Development Hub has been working on initiating a global implementation programme for the FIP global workforce development roadmap, including the Pharmaceutical Workforce Development Goals. The programme was launched in April 2019. FIP also began planning a side event with the World Health Organization for the 2019 World Health Assembly.

NON-COMMUNICABLE DISEASES

An FIP working group developed a reference paper on the role and impact of community pharmacists in non-communicable diseases, through prevention, screening, referral and management activities, which has recently been published (April 2019).

PATIENT SAFETY

FIP is preparing a reference document outlining the pharmacist’s role in patient safety. Such tools not only benefit governments but also support national associations of pharmacists in being fully engaged in the development of patient safety policies.

MEDICINES FOR CHILDREN

FIP’s Special Interest Group on Formulation Design and Pharmaceutical Technology initiated a project, working with members of our Health and Medicines Information Section, Hospital Pharmacy Section and Special Interest Group on Regulatory Science, to improve the education of future pharmacists in the area of better formulation of paediatric medicines.

EDUCATION AND ACADEMIC DEVELOPMENT

FIP’s Academic Pharmacy Section has been developing a Nanjing Statements self-assessment tool and users guide. This work is critical to the implementation of the Nanjing Statements 2016 and will allow users, primarily education institutions and academic leaders, to assess progress and evaluate their own development.

PRIMARY HEALTH CARE

FIP began working on a series of regional conferences to take forward the global imperative for further developing pharmacy’s place in primary health care. The first conference (for the Eastern Mediterranean Region) was held in Amman, Jordan, in April 2019.
## FINANCES

### BALANCE SHEET AT 31 DECEMBER 2018

After appropriation of the results for 2018
Expressed in EURO

<table>
<thead>
<tr>
<th></th>
<th>31 DECEMBER 2018</th>
<th>31 DECEMBER 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Intangible fixed assets</strong></td>
<td>62,178</td>
<td>53,343</td>
</tr>
<tr>
<td><strong>FIXED ASSETS</strong></td>
<td>632,651</td>
<td>566,814</td>
</tr>
<tr>
<td><strong>CURRENT ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Debtors, prepayments and accrued income</td>
<td>476,889</td>
<td>353,302</td>
</tr>
<tr>
<td>Cash at bank and in hand</td>
<td>2,307,796</td>
<td>2,329,123</td>
</tr>
<tr>
<td><strong>TOTAL CURRENT ASSETS</strong></td>
<td>2,784,685</td>
<td>2,682,426</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td>3,479,514</td>
<td>3,302,583</td>
</tr>
<tr>
<td><strong>CAPITAL AND RESERVES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Capital FIP</td>
<td>1,089,151</td>
<td>1,091,163</td>
</tr>
<tr>
<td>Capital FIP sections</td>
<td>668,888</td>
<td>592,653</td>
</tr>
<tr>
<td>Congress reserve</td>
<td>650,000</td>
<td>650,000</td>
</tr>
<tr>
<td>Board of Pharmaceutical Practice reserve</td>
<td>121,703</td>
<td>107,523</td>
</tr>
<tr>
<td>Board of Pharmaceutical Sciences reserve</td>
<td>141,205</td>
<td>132,407</td>
</tr>
<tr>
<td>Reserve FIPc</td>
<td>235,959</td>
<td>181,724</td>
</tr>
<tr>
<td><strong>TOTAL CAPITAL AND RESERVES</strong></td>
<td>2,906,906</td>
<td>2,755,470</td>
</tr>
<tr>
<td><strong>PROVISIONS</strong></td>
<td>30,957</td>
<td>23,057</td>
</tr>
<tr>
<td><strong>CURRENT LIABILITIES</strong></td>
<td>541,651</td>
<td>524,056</td>
</tr>
<tr>
<td><strong>TOTAL CAPITAL AND RESERVES AND LIABILITIES</strong></td>
<td>3,479,514</td>
<td>3,302,583</td>
</tr>
</tbody>
</table>
## INCOME

<table>
<thead>
<tr>
<th>Source</th>
<th>ACTUALS 2018</th>
<th>BUDGET 2018</th>
<th>BUDGET vs ACTUALS</th>
<th>ACTUALS 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Membership fees</td>
<td>1,230,203</td>
<td>1,085,000</td>
<td>145,203</td>
<td>1,169,135</td>
</tr>
<tr>
<td>Congress revenues</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- FIP annual congress</td>
<td>1,780,234</td>
<td>1,650,000</td>
<td>130,234</td>
<td>1,313,116</td>
</tr>
<tr>
<td>- PSWC 2017 congress</td>
<td></td>
<td></td>
<td></td>
<td>609,714</td>
</tr>
<tr>
<td>Publications</td>
<td></td>
<td>4,000</td>
<td>(4,000)</td>
<td></td>
</tr>
<tr>
<td>Other income BPS</td>
<td>5,459</td>
<td></td>
<td>5,459</td>
<td>3,880</td>
</tr>
<tr>
<td>Section income</td>
<td>143,946</td>
<td>95,000</td>
<td>48,946</td>
<td>103,375</td>
</tr>
<tr>
<td>FIP ED income</td>
<td>26,731</td>
<td></td>
<td>26,731</td>
<td>338,423</td>
</tr>
<tr>
<td>Corporate roundtable income/external partnership</td>
<td>194,201</td>
<td>200,000</td>
<td>(5,799)</td>
<td>12,078</td>
</tr>
<tr>
<td>Other income</td>
<td>24,388</td>
<td>60,000</td>
<td>(35,612)</td>
<td>1,203</td>
</tr>
<tr>
<td><strong>TOTAL INCOME</strong></td>
<td><strong>3,405,162</strong></td>
<td><strong>3,094,000</strong></td>
<td><strong>311,162</strong></td>
<td><strong>3,350,924</strong></td>
</tr>
</tbody>
</table>

## EXPENSES

<table>
<thead>
<tr>
<th>Category</th>
<th>ACTUALS 2018</th>
<th>BUDGET 2018</th>
<th>BUDGET vs ACTUALS</th>
<th>ACTUALS 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Membership costs</td>
<td>189,922</td>
<td>100,000</td>
<td>89,922</td>
<td>190,830</td>
</tr>
<tr>
<td>Personnel costs</td>
<td>1,053,635</td>
<td>990,000</td>
<td>63,635</td>
<td>996,609</td>
</tr>
<tr>
<td>Office costs</td>
<td>162,442</td>
<td>140,000</td>
<td>22,442</td>
<td>166,001</td>
</tr>
<tr>
<td>Meeting costs</td>
<td>61,765</td>
<td>120,000</td>
<td>(58,235)</td>
<td>71,202</td>
</tr>
<tr>
<td>Travel expenses external representation</td>
<td>51,044</td>
<td>50,000</td>
<td>1,044</td>
<td>36,830</td>
</tr>
<tr>
<td>Strategic plan</td>
<td>21,586</td>
<td>80,000</td>
<td>(58,414)</td>
<td>42,884</td>
</tr>
<tr>
<td>Website and IT</td>
<td>118,708</td>
<td>80,000</td>
<td>38,708</td>
<td>110,212</td>
</tr>
<tr>
<td>Depreciation of fixed assets</td>
<td>21,160</td>
<td>25,000</td>
<td>(3,840)</td>
<td>27,727</td>
</tr>
<tr>
<td>Other (special) projects</td>
<td>85,878</td>
<td>15,000</td>
<td>70,878</td>
<td>17,246</td>
</tr>
<tr>
<td>FIP congress costs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- FIP annual congress</td>
<td>1,052,761</td>
<td>1,000,000</td>
<td>52,761</td>
<td>801,271</td>
</tr>
<tr>
<td>- PSWC 2017 congress</td>
<td></td>
<td></td>
<td>(620,232)</td>
<td></td>
</tr>
<tr>
<td>Publications</td>
<td>51,959</td>
<td>60,000</td>
<td>(8,041)</td>
<td>36,204</td>
</tr>
<tr>
<td>Subventions</td>
<td>20,587</td>
<td>22,000</td>
<td>(1,413)</td>
<td>25,084</td>
</tr>
<tr>
<td>Expenses BPP</td>
<td>83,820</td>
<td>99,000</td>
<td>(15,180)</td>
<td>88,122</td>
</tr>
<tr>
<td>Expenses BPS</td>
<td>34,661</td>
<td>63,000</td>
<td>(28,339)</td>
<td>40,915</td>
</tr>
<tr>
<td>Sections’ operating costs</td>
<td>67,711</td>
<td>95,000</td>
<td>(27,289)</td>
<td>50,906</td>
</tr>
<tr>
<td>FIP ED expenses</td>
<td>142,871</td>
<td>186,600</td>
<td>(43,729)</td>
<td>88,450</td>
</tr>
<tr>
<td>Building Maintenance Fund</td>
<td>15,000</td>
<td>15,000</td>
<td>(16,097)</td>
<td>435</td>
</tr>
<tr>
<td>Business development</td>
<td>5,903</td>
<td>20,000</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TOTAL EXPENSES</strong></td>
<td><strong>3,241,413</strong></td>
<td><strong>3,160,600</strong></td>
<td><strong>80,813</strong></td>
<td><strong>3,426,151</strong></td>
</tr>
</tbody>
</table>

## OPERATING RESULT

<table>
<thead>
<tr>
<th>Category</th>
<th>ACTUALS 2017</th>
<th>BUDGET 2017</th>
<th>BUDGET vs ACTUALS</th>
<th>ACTUALS 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operating result</td>
<td>163,749</td>
<td>(66,600)</td>
<td>230,249</td>
<td>(75,228)</td>
</tr>
<tr>
<td>Financial result</td>
<td>(12,313)</td>
<td>15,000</td>
<td>(27,313)</td>
<td>(11,779)</td>
</tr>
<tr>
<td><strong>NET RESULT BEFORE APPROPRIATION</strong></td>
<td><strong>151,436</strong></td>
<td><strong>(51,600)</strong></td>
<td><strong>203,036</strong></td>
<td><strong>(87,006)</strong></td>
</tr>
</tbody>
</table>

## Appropriation of the results

<table>
<thead>
<tr>
<th>Category</th>
<th>ACTUALS 2017</th>
<th>BUDGET 2017</th>
<th>BUDGET vs ACTUALS</th>
<th>ACTUALS 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>BPP general reserves</td>
<td>14,180</td>
<td>3,500</td>
<td>10,680</td>
<td>9,888</td>
</tr>
<tr>
<td>BPS general reserves</td>
<td>8,798</td>
<td>(9,500)</td>
<td>18,298</td>
<td>965</td>
</tr>
<tr>
<td>Section capital</td>
<td>76,235</td>
<td></td>
<td>76,235</td>
<td>52,469</td>
</tr>
<tr>
<td>Reserve FIPED</td>
<td>54,235</td>
<td></td>
<td>54,235</td>
<td>49,973</td>
</tr>
<tr>
<td>Reserve HIV/AIDS</td>
<td></td>
<td></td>
<td>(5,000)</td>
<td></td>
</tr>
<tr>
<td>FIP capital</td>
<td>(2,012)</td>
<td>(45,600)</td>
<td>43,588</td>
<td>(195,300)</td>
</tr>
<tr>
<td><strong>TOTAL APPROPRIATION</strong></td>
<td><strong>151,436</strong></td>
<td><strong>(51,600)</strong></td>
<td><strong>203,036</strong></td>
<td><strong>(87,006)</strong></td>
</tr>
</tbody>
</table>